{"id":"W4291019728","doi":"10.2217/fon-2022-0484","title":"Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Rosetrees Trust; Cancer Research UK","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Placebo; Clinical trial; Oncology; Extramedullary hematopoiesis; Bone marrow; Haematopoiesis; Pathology; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002428198,0.002081517,0.002649994,0.0005147458,0.0004293114,0.001557684,0.001338837,0.001991296,0.008080728],"category_scores_gemma":[0.001424909,0.0007302813,0.001819538,0.000407183,0.001225254,0.001351708,0.0005286559,0.003737227,0.001462661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008967637,"about_ca_system_score_gemma":0.001370436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006859622,"about_ca_topic_score_gemma":0.001604049,"domain_scores_codex":[0.9994524,0.0002834822,0.00003054643,0.00008064493,0.00004468433,0.0001082984],"domain_scores_gemma":[0.9992734,0.0001411428,0.0001924816,0.00007382977,0.00006807112,0.000251201],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9263062,0.03241385,0.000644197,0.001042583,0.000750591,0.00006389369,0.00008437909,0.0007983129,0.01054135,0.0003161995,0.002736674,0.02430181],"study_design_scores_gemma":[0.8411897,0.1543238,0.001595927,0.00004654545,0.0002088391,0.00004933694,0.00003540174,0.0003627182,0.0009032508,0.0001680026,0.001101308,0.00001500452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9662924,0.007972532,0.001454409,0.001384486,0.0008733924,0.0126647,0.00428293,0.0004683224,0.004606822],"genre_scores_gemma":[0.9575067,0.00539423,0.003709649,0.002702853,0.0009683568,0.01501786,0.005535427,0.000108706,0.009056184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008080728,"threshold_uncertainty_score":0.02703273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02084345738915811,"score_gpt":0.3262002128301859,"score_spread":0.3053567554410278,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}